Skip to main content
. Author manuscript; available in PMC: 2013 Sep 11.
Published in final edited form as: Menopause. 2010 Sep-Oct;17(5):946–954. doi: 10.1097/gme.0b013e3181d76953

Table 5.

Multivariable Adjusted1 Risk of Incident Symptoms at Post-stopping2 by Prevalence of Symptoms Prior to Stopping3: WHI CEE sub-sample (n=3496)4

Symptom Prevalence Prior to Stopping CEE %5 (N)6 Placebo % (N) RR (95% CI)7 P8 P-int9
Hot Flashes
 Not present 9.3 (1640) 2.2 (1663) 3.64 (2.54, 5.20) <0.001 <0.001
 Present 35.3 (34) 30.6 (62) 0.85 (0.44, 1.64)
Night Sweats
 Not Present 9.3 (1588) 3.4 (1610) 2.30 (1.69, 3.13) <0.001 0.008
 Present 46.4 (84) 36.8 (114) 1.18 (0.82, 1.71)
Breast Sensitivity
 Not Present 1.8 (1589) 1.2 (1688) 1.66 (0.89, 3.09) 0.03 0.41
 Present 18.1 (83) 17.8 (45) 1.06 (0.47, 2.39)
Vaginal Dryness
 Not Present 3.2 (1546) 2.4 (1586) 1.36 (0.87, 2.11) 0.87 0.12
 Present 32.2 (118) 30.9 (136) 0.85 (0.58, 1.25)
Joint Pain
 Not Present 18.3 (1146) 15.4 (1231) 1.24 (1.02, 1.51) <0.001 0.47
 Present 64.6 (511) 55.1 (497) 1.14 (1.03, 1.27)
Mood Swings
 Not Present 3.4 (1561) 2.8 (1624) 1.17 (0.77, 1.78) 0.54 0.80
 Present 34.0 (103) 29.0 (100) 1.27 (0.79, 2.05)
1

Adjusted for age at prior to stopping, years since menopause, prior hormone use and presence of baseline vasomotor symptoms.

2

Incidence of moderate or severe symptoms after stopping study pills.

3

Prevalence of moderate or severe symptoms prior to stopping study pills.

4

Women that were eligible (were not deceased, stopped or lost to follow-up and were still taking study pills) and completed all surveys.

5

Proportion of N reporting symptoms post-stopping.

6

Number of participants in CEE or placebo with or without symptom prior to stopping, denominator of (5).

7

Multivariate adjusted relative risk (95% confidence interval) of symptoms at post-stopping of CEE compared to placebo.

8

Test of main effect.

9

Test of interaction.